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BACKGROUND: Even though medications can greatly
reduce the risk of recurrent stroke, medication adher-
ence is suboptimal in stroke survivors.
OBJECTIVE: To identify key barriers to medication
adherence in a predominantly low-income, minority
group of stroke and transient ischemic attack (TIA)
survivors.
DESIGN: Cross-sectional study.
PARTICIPANTS: Six hundred stroke or TIA survivors,
age ≥ 40 years old, recruited from underserved com-
munities in New York City.
MAIN MEASURES: Medication adherence was mea-
sured using the 8-item Morisky Medication Adherence
Questionnaire. Potential barriers to adherence were
assessed using validated instruments. Logistic regres-
sion was used to test which barriers were indepen-
dently associated with adherence. Models were
additionally controlled for age, race/ethnicity, income,
and comorbidity.
KEY RESULTS: Forty percent of participants had poor
self-reported medication adherence. In unadjusted
analyses, compared to adherent participants, non-
adherent participants had increased concerns about
medications (26 % versus 7 %, p<0.001), low trust in
their personal doctor (42 % versus 29 %, p=0.001),
problems communicating with their doctor due to
language (19 % versus 12 %, p=0.02), perceived
discrimination from the health system (42 % versus
22 %, p<0.001), difficulty accessing health care (16 %
versus 8 %, p=0.002), and inadequate continuity of
care (27 % versus 20 %, p=0.05). In the fully adjusted
model, only increased concerns about medications [OR
5.02 (95 % CI 2.76, 9.11); p<0.001] and perceived
discrimination [OR 1.85 (95 % CI 1.18, 2.90); p=
0.008] remained significant barriers.
CONCLUSIONS: Increased concerns about medications
(related to worry, disruption, long-term effects, and
medication dependence) and perceived discrimination
were the most important barriers to medication ad-
herence in this group. Interventions that reduce
medication concerns have the greatest potential to
improve medication adherence in low-income stroke/
TIA survivors.
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INTRODUCTION
Stroke is the fourth leading cause of death and a leading
cause of severe physical disability in US adults.1 Medi-
cations from several classes, including antiplatelet agents,
antihypertensives, and statins, substantially reduce the risk
of both incident and recurrent stroke.2, 3 Yet, adherence to
medications is suboptimal in stroke survivors. In one
study of 2,598 patients discharged from the hospital after
stroke or transient ischemic attack (TIA), approximately
one in four participants discontinued one or more of their
stroke prevention medications within 3 months of
discharge,4 and in another study of 3,571 stroke survi-
vors, approximately one-third of patients had suboptimal
adherence to antihypertensive medications in the year
following their stroke.5
Although researchers have begun to identify predictors
of non-adherence to medications for cardiovascular dis-
ease,6, 7 comparatively few have assessed barriers to
medication adherence, particularly in stroke survivors.4, 5, 8, 9
Predictors of adherence encompass patient factors such as
age, income level, or years of education that can be used to
identify patients most in need of adherence interventions,
but that cannot necessarily be directly modified. Barriers
to adherence, in contrast, are restricted to potentially
modifiable factors that physicians and/or the health care
system can attempt to overcome to reduce medication non-
adherence.6 An understanding of the key barriers to
medication adherence in stroke survivors has great potential
to inform novel approaches to reducing non-adherence in this
population.
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Stroke disproportionately affects patients from low
income and minority groups,10, 11 and members of these
groups have traditionally been under-represented in re-
search studies.12 Accordingly, we assessed barriers to
medication adherence in a predominantly low-income,
minority sample of stroke and TIA survivors. The concep-
tual model used to identify potential barriers to medication
adherence in the present study was adapted from a model
by Osterberg and Blaschke.6 According to this model,
barriers are organized into those that stem from interactions
between: 1) the patient and their health providers, 2) the
patient and the health care system, and 3) health providers
and the health care system (Fig. 1). The current study
focuses on patients’ interactions with health providers and
systems.
The hypothesis regarding the barriers that would be most
strongly associated with poor adherence was informed by
Leventhal’s theory of self-regulation.13 According to this
theory, patients’ health behaviors are determined by
patients’ common sense understanding of their illness.
When patients’ understanding fits a model that is consistent
with adherence to recommended treatments, then it is
predicted that patients will be more adherent. Horne and
Weinman expanded this theory to incorporate the notion
that patients’ common-sense beliefs about medications are
key to determining whether patients will adhere to
medications.14 Accordingly, we hypothesized that barriers
related to medication beliefs would be most strongly
associated with medication adherence. Although patients’
beliefs about medications come from many sources,
including personal experience, the experiences of friends
and family members, or the media, barriers related to
medication beliefs fall within patient–health provider
interactions in the Osterberg and Blaschke model, as
clinicians also have the potential to strongly influence these
beliefs. As an exploratory analysis, we also tested whether
the pattern of barriers differed by race or ethnicity.
METHODS
Recruitment
Participants were recruited as part of a clinical trial,
Preventing Recurrence of All Inner City Strokes (PRAISE),
which tests an intervention to improve adherence to risk-
reducing behaviors in stroke survivors. Details of the study
design have been published elsewhere,15 but briefly,
participants were eligible if they were at least 40 years of
age and if they self-reported a history of stroke or TIA in
the prior 5 years. Participants were excluded if they had
significant aphasia, cognitive impairment, or other neuro-
logic deficits that would preclude them from providing
informed consent or from meaningfully participating in
classes teaching self-management skills. Proxies could not
provide consent on behalf of participants. Additionally,
participants were excluded if they had a terminal illness,
were pregnant, spoke languages other than Spanish or
English, or resided in institutionalized settings. Spanish
speaking participants were interviewed by bilingual study
personnel, and were surveyed using materials that were
translated into Spanish and then back-translated into
English. All data presented in this manuscript come from
the baseline interviews that took place prior to randomiza-
tion into the clinical trial. Ethics approval was obtained
from the Institutional Review Board of the Mount Sinai
School of Medicine. All participants provided written
informed consent.
Figure 1. Conceptual model of barriers to medication adherence in stroke survivors. Model adapted from Osterberg and Blaschke.6
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Medication Adherence
Adherence to medications was measured using the 8-item
Morisky Medication Adherence Questionnaire (Morisky).16
Sample items include “Do you sometimes forget to take
your medicine?” and “Have you ever cut back or stopped
taking your medicine without telling your doctor because
you felt worse when you took it?” The questionnaire has
been validated against an objective measure of adherence17
and has been used in racially diverse and elderly patient
samples.18 Scores on the questionnaire can be used to
classify patients into low and high adherence groups.
Consistent with standard cut points, participants who scored
less than 6 points on the Morisky were categorized as non-
adherent to medications and participants who scored 6 to
8 points were categorized as adherent.16
Adherence Barriers Related to Interactions
Among Health Care Providers and Patients
Concerns about medications were measured by adapting
four items from the Concerns subscale of the Beliefs about
Medicines Questionnaire (BMQ).19 Three items ask partic-
ipants to rate the degree to which they worry about “having
to take your medicines”, “long-term effects of your
medicines”, and “becoming too dependent on your medi-
cines.” The fourth item asks how much “medicines disrupt
your life.” Questions were modified from the original
instrument to make them more understandable for a study
population at risk for mild cognitive impairment and low
health literacy. Specifically, instead of asking participants to
read each item and then rate their agreement with it,
participants were directly asked each question by the
interviewer. In addition, the response scale for the included
items was reduced from the usual five options (“strongly
disagree” to “strongly agree”) to four options (1-“not at
all”, 2-“a little bit”, 3-“somewhat” and 4-“very much”).
Finally, one of the five items on the original scale (“My
medicines are a mystery to me” was omitted as partic-
ipants had difficulty understanding this item, even in the
adapted format. The four items were averaged for a mean
Concerns score. A cut-point of 2.5, the midpoint of the
scale, was used to dichotomize participants into having
high versus low concerns. Cronbach’s α for the scale in
this sample was 0.71.
Perceived necessity of medications was measured by
adapting the Necessity subscale of the BMQ.19 The five
items ask participants to rate how much “your health
depends on your medications”, they would be “ill without
your medications”, “your health in the future depends on
your medications”, “your life would be impossible without
your medications”, and “your medicines protect you from
becoming worse.” Participants were given the same
response options as for the Concerns items, and the five
items were averaged for a mean Necessity score. A cut-
point of 3 was used to dichotomize participants into having
high versus low perceived benefits of medications. Cron-
bach’s α for the scale in this sample was 0.80.
Knowledge of their disease was assessed by asking
participants to state the three most important things they
would recommend to others to lower the risk of having a
stroke. Participants who could not name more than one of
the three most important risk-reducing behaviors20 (i.e.,
taking antihypertensive medications or controlling blood
pressure; taking cholesterol-lowering medications for con-
trolling cholesterol; or taking aspirin or other medications to
thin the blood) were considered to have poor understanding
of how to prevent recurrent stroke.
Trust in doctors was assessed using three items adapted
from the Trust in Doctors scale.21 Specifically, participants
were asked how much they felt “you could tell your doctor
anything”, how often they thought their doctor “put your
best interests first”, and “all things considered, how much
do you trust your personal doctor?” Response options for
the first two items were scored 1-“never”, 2-“sometimes”,
3-“always”, and the third item was scored -1-“not at all”, 2-
“a little bit”, 3-“somewhat”, and 4-“very much”, with
higher scores signifying increased trust. The median score
was used to dichotomize participants into having low versus
high trust in their personal doctor.
Difficulty communicating with doctors due to language
was assessed by asking participants how often they had a
hard time speaking or understanding their health providers
because they spoke different languages. Participants were
given the options “always”, “sometimes”, or “never” and
were categorized as having language problems if they
responded “always” or “sometimes”. This item was adapted
from the CAHPS 4.0 survey.
Barriers Related to Interactions
Among Patients and the Health Care System
Perceived discrimination was assessed by asking partic-
ipants how often (“always”, “often”, “sometimes”, “rarely”,
“never”) they felt discriminated against by doctors or staff
at their clinic because of their 1) race or ethnicity or 2)
education or income.22 Participants who answered “some-
times”, “often”, or “always” on either item were categorized
as perceiving discrimination from the health system.
Difficulty accessing medical care was assessed by asking
participants how difficult it was for them to get medical care
when they needed it. Participants who answered “some-
what”, or “very much” were categorized as having prob-
lems accessing medical care.23
Poor continuity of care was assessed by asking partic-
ipants if they usually got to see the same doctor when they
went to their primary care visit. Participants who answered
“no” or who reported not having a primary care doctor were
677Kronish et al.: Barriers to Medication Adherence after StrokeJGIM
categorized as having poor continuity of care. This item was
adapted from the Consumer Assessment of Healthcare
Providers and Systems (CAHPS) 4.0 survey.
Problems due to medication cost were assessed by asking
participants if they were worried about the cost of their
medicines, and if they ever skipped a medicine or took a
smaller dose to make the medicine last longer because they
were concerned about cost.24 If participants answered “yes”
to either item they were categorized as having problems due
to medication cost.
Additional factors assessed to describe the participants
included demographic factors (age, gender, race/ethnicity,
annual household income, and health insurance type) and
medical history. Stroke severity was measured at the time of
enrollment into the study using the modified Rankin
scale;25 a score of 3 or higher on this scale signifies at
least moderate functional disability. When answering ques-
tions pertinent to the Rankin scale, participants were asked
to report on functional problems that occurred as a result of
symptoms from their stroke. Stroke timing was measured
by asking the year of the most recent stroke or TIA.25
Comorbidity was measured using the Charlson comorbidity
index.26
Analysis Plan
Chi-squared and t-tests were used to compare characteristics
of participants according to whether they were or were not
adherent to medications. Spearman’s correlation was used
to measure the correlation between number of barriers and
adherence. Logistic regression was used to calculate the
unadjusted and adjusted odds ratios and 95 % confidence
intervals for the association between barriers to adherence
and non-adherence. For the primary analysis, barriers were
entered as categorical variables (e.g., high versus low trust
in physicians). The adjusted model was repeated by
entering barriers as continuous measures in cases where
barriers were measured using a scaled instrument (e.g., total
score on trust in personal doctor scale). Adjusted models
were additionally controlled for demographics (age, gender,
race/ethnicity, income, years of education) and medical
history (modified Rankin, Charlson) as these factors have
been associated with medication adherence in prior studies.4
Adjusted analyses were repeated for African American and
Hispanic subgroups. Analyses were performed using SPSS
statistical software (version 18; SPSS Inc, Chicago, IL).
RESULTS
The mean age of participants was 63 years, about 60 %
were women, and a majority of participants were non-white
and had low income (Table 1). Spanish was the preferred
language in 24 % of participants. Overall, 40 % of
participants were non-adherent to medications. Younger
age, non-white race/ethnicity, and increasing comorbidity
were all associated with medication non-adherence.
Among the possible barriers to medication adherence,
participants most commonly reported poor knowledge of
stroke prevention therapies (77 %), low trust in their
personal doctor (34 %), problems due to medication cost
(32 %), and perceived discrimination by the health system
(30 %) (Table 2). A similar number of participants
perceived discrimination due to race/ethnicity (25 %), as
compared to discrimination due to education or income
(22 %). There was a modest correlation between increasing
number of barriers and non-adherence to medications
(Spearman’s rho 0.25, p<0.001; Fig. 2).
In unadjusted analyses (Table 2), the following barriers
were significantly (p<0.05) more common in non-adherent
participants compared to those who were adherent: in-
creased concerns about medications, low trust in doctor,
problems communicating with doctors due to language
problems, perceived discrimination by the health care
Table 1. Characteristics of Participants According to Medication Adherence Status
Characteristic Overall (N=600) Adherent; N=358 (59.7 %) Non-adherent; N=242 (40.3 %) P-value
Age, mean (SD), in years 63.4 (11.2) 65.1 (11.4) 60.9 (10.5) < 0.001
Female gender 356 (59.4) 203 (56.7) 153 (63.5) 0.10
Race/ethnicity*
White 96 (16.0) 67 (18.7) 29 (12.0) 0.03
Black 280 (46.7) 164 (45.8) 116 (47.9) 0.61
Hispanic 216 (36.0) 122 (34.1) 94 (38.8) 0.23
Other 42 (7.0) 25 (7.0) 17 (6.0) 0.98
Income < $15,000 341 (58.6) 194 (59.4) 147 (62.6) 0.11
Less than high school education 182 (30.5) 109 (30.6) 73 (30.4) 0.96
Prescription insurance coverage 573 (96.6) 348 (97.5) 225 (95.3) 0.16
Preferred language Spanish 141 (23.5) 89 (24.9) 52 (21.6) 0.35
Modified Rankin score > 2 280 (46.7) 160 (44.7) 120 (49.6) 0.24
Charlson score, mean (SD) 3.6 (2.1) 3.4 (2.0) 4.0 (2.3) 0.005
Data are presented as number (%) unless otherwise specified in the Table. Numbers do not always add up to 100 % due to missing cases. Fewer
than 3 % missing for each variable
*Percentages add up to more than 100 %, as participants could choose more than one category
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system, difficulty accessing health care, and poor continuity
of medical care.
In the fully adjusted model (Table 3), the only barriers
that remained significantly associated with medication
non-adherence included increased concerns about medi-
cations [OR 5.1 (95 % CI 2.8 to 9.2)] and perceived
discrimination on account of race, ethnicity, education or
income [OR 1.8 (95 % CI 1.1 to 2.8)]. Age was also
associated with adherence; older patients were less likely
to be non-adherent.
In a subgroup analysis restricted to Hispanics, both
increased concerns about medications [OR 6.9 (95 % CI
2.7 to 17.1)] and perceived discrimination [OR 3.1 (95 %
CI 1.4 to 7.0)] were associated with non-adherence. In a
subgroup analysis of African American participants, only
increased concerns about medications [OR 7.2 (95 % CI 2.7
to 19.3] were associated with non-adherence, although
perceived discrimination had a similar direction of associ-
ation that did not reach statistical significance [OR 1.6
(95 % CI 0.8 to 3.1)].
DISCUSSION
In our sample of community-dwelling survivors of strokes
and TIAs without substantial cognitive impairment, we
found that among the nine barriers assessed, increased
concerns about medications—present in nearly 25 % of
non-adherent participants—was by far the most important
barrier to medication adherence. Participants with increased
concerns about medications had five times increased odds
of non-adherence as compared to those without increased
concerns. Perceived discrimination by the health care
system due to race, ethnicity, education, or income was
another significant barrier to adherence. None of the other
barriers in the model proposed by Osterberg and Blaschke,6
at least as measured by this study, were significant
independent predictors of non-adherence.
There is a large body of research demonstrating that
beliefs about medications in general, and concerns in
particular, are associated with adherence to medications
prescribed for chronic illnesses.8, 14, 27–29 This analysis
adds to the literature by showing that in comparison with
other possible barriers to medication adherence, concerns
about medications, such as becoming dependent on them or
worrying about their long-term consequences, have the
strongest association with non-adherence and hence repre-
sent a key barrier to overcoming non-adherence, at least in
our group of stroke and TIA survivors.
The association we found between perceived discrimina-
tion and non-adherence has been demonstrated in other
patient populations such as HIV-infected individuals, and in
studies of adherence to other types of recommended health
behaviors.30–33 Amongst certain minorities, there is a
history of discrimination that continues to inform current
perceptions about health care and can lead to distrust in
treatments espoused by the health care system.34 Interest-
ingly, in our subgroup analysis, we found that perceived
discrimination was a barrier to medication adherence in
Hispanics, but not in African Americans. This was
surprising as, in some studies, African Americans are
equally or more likely to report distress from perceived
Table 2. Prevalence of Barriers to Medication Adherence in Patients Who Were and Were Not Adherent to Medications





Barriers Related to Interactions between Patients and their Personal Doctor
Increased concerns about medications 85 (14.4) 23 (6.5) 62 (26.4) < 0.001
Low perceived necessity of medications 150 (26.6) 87 (25.7) 63 (28.0) 0.55
Poor understanding of stroke prevention 466 (77.7) 272 (76.0) 194 (80.2) 0.23
Low trust in personal doctor 205 (34.2) 103 (28.8) 102 (42.1) 0.001
Problems communicating with doctor due to language 90 (15.1) 44 (12.3) 46 (19.3) 0.02
Barriers Related to Interactions between Patients and the Health System
Perceive discrimination due to race/ethnicity or education/income 175 (30.0) 75 (21.6) 100 (42.2) < 0.001
Problems due to medication cost 196 (32.8) 110 (30.7) 86 (36.0) 0.18
Difficulty accessing health care 68 (11.4) 29 (8.1) 39 (16.3) 0.002
Lack continuity of care 132 (22.6) 69 (19.8) 63 (26.7) 0.05
Data presented as number (%). Numbers do not always add up to 100 % due to missing cases; Fewer than 3% missing for all variables other than
perceived necessity of medication, for which 6.3 % of responses were missing
Figure 2. Association between number of barriers and adherence
to medications in survivors of strokes and transient ischemic
attacks.
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discrimination on account of minority status as compared to
Hispanics.35 This finding reinforces the importance of
training clinicians and staff to understand these perceptions,
particularly among Hispanics, and to try to overcome them
through improved communication and trust. Further, inter-
ventions might aim to empower stroke survivors and their
caregivers to learn how to advocate for the best treatments
available, irrespective of how others in the health care
system treat them.
Even though our sample had a large number of low-
income participants and nearly one-third reported at least
some problems due to medication cost, concerns about
medication costs were not an important barrier to medica-
tion adherence in this sample. This may be partially
explained by the fact that almost all participants, including
low-income ones, had at least some prescription insurance
and New York State provides low out-of-pocket costs for
Medicaid beneficiaries. As such, copays for beneficiaries
are rarely prohibitive. Furthermore, an increasing number of
pharmacies now offer a wide variety of generic prescrip-
tions at reasonable prices, even for those without good
coverage. Even when patients have some trouble affording
medications, they may be willing to find a way to pay for
the medications if they believe the medications are
important enough.36 Interestingly, in a recent randomized
clinical trial, providing full prescription coverage for
cardiovascular medications to patients enrolled in a health
maintenance organization who had suffered a myocardial
infarction resulted in modest improvements in medication
adherence.37
There are several limitations that should be considered in
the interpretation of our findings. First, adherence was
measured using self-report, and objective measures of
adherence were not available to confirm responses. Further,
the scale used to measure adherence did not specifically ask
about adherence to stroke medications, and has not
previously been validated in stroke survivors. Nevertheless,
self-report measures of adherence are often highly correlat-
ed with objective measures,17 and have been reliable
predictors of poor outcomes in multiple studies.38, 39 If
anything, self-reports may have underestimated the true
prevalence of non-adherence in our sample.40 Stroke/TIA
history was also based on self-report and was not confirmed
by review of medical records; this may have led to the
inclusion of some participants who did not have a
cerebrovascular event. Another limitation is that the
inclusion of a large number of low income African
Americans and Hispanic participants may limit the gener-
alizability of our findings to other study populations.
However, given the fact that there are unexplained
disparities in stroke outcomes, the diversity of our sample
can also be viewed as a strength of our study, especially
since these groups are often understudied and may be at
increased risk for non-adherence.41 Some of our measures
of barriers to adherence, such as concerns about medica-
tions, were modified from previously validated scales (e.g.,
BMQ). Nevertheless, we carefully adapted these questions
to be more easily understood by our study population. Our
choices for cut-points for categorizing participants as having
increased concerns about medications, low perceived neces-
sity of medications, and low trust in doctors were made
empirically, and hence, estimates of the proportion of
participants with each of these barriers should be interpreted
with caution. Finally, additional potential barriers to medica-
tion adherence such as medication regimen complexity, low
quality of provider communication, and lack of social
support were not assessed by the study. In particular, lack of
collaborative, patient-centered communication has been
associated with non-adherence in prior studies.42 Caregiver
support may also be particularly important for maintaining
medication adherence in stroke survivors who have physical
and cognitive limitations as a result of their stroke.
Nevertheless, our selection of barriers was guided by a
widely referenced conceptual model and we assessed nearly
all of the patient-related barriers in this model.6 Finally, one
should extrapolate our results to cognitively impaired stroke
survivors with caution, as only cognitively intact stroke
survivors were included in this analysis.
Table 3. Unadjusted and Adjusted Associations between Barriers to Adherence and Non-Adherence to Medications in Survivors of Strokes
and Transient Ischemic Attacks
Potential barriers to medication adherence Unadjusted P-Value Adjusted* P-Value
Odds ratio (95 % CI) Odds ratio (95 % CI)
High concerns about medications 5.19 (3.11, 8.66) < 0.001 5.09 (2.81, 9.24) < 0.001
Low perceived need for medications 1.12 (0.77, 1.64) 0.55 1.23 (0.79, 1.91) 0.36
Low knowledge of stroke risk factors 1.28 (0.86, 1.90) 0.23 1.22 (0.76, 1.96) 0.42
Low trust in personal doctor 1.80 (1.28, 2.54) 0.001 1.30 (0.84, 2.01) 0.23
Problems due to language 1.71 (1.09, 2.68) 0.02 1.32 (0.76, 2.29) 0.32
Perceive discrimination due to race,
ethnicity, education, or income
2.65 (1.84, 3.81) < 0.001 1.79 (1.14, 2.81) 0.01
Problems due to medication cost 1.27 (0.90, 1.79) 0.18 0.87 (0.57, 1.32) 0.50
Difficulty accessing health care 2.20 (1.32, 3.66) 0.003 1.32 (0.70, 2.48) 0.40
Lack continuity of care 1.47 (1.00, 2.18) 0.05 1.09 (0.68, 1.74) 0.73
*This model adjusted for all nine barriers and the following additional covariates: age, gender, race/ethnicity, income, education, Charlson. The
only additional covariate associated with non-adherence was age [OR 0.97 (95 % CI 0.96, 0.99); p<0.001]
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These limitations notwithstanding, our results should be
helpful for informing the design of interventions to help
stroke and TIA survivors improve their adherence to
medications through modifying concerns about medica-
tions. In fact, the intervention that is being tested in the
parent study15 may be particularly well suited to overcom-
ing the barriers identified in this analysis. In this interven-
tion, peer-leaders lead community-based workshops that
teach stroke and TIA survivors how to better self-manage
their health in order to decrease their risk of recurrent
cerebrovascular events. This format may be particularly
well-suited to providing patients with an opportunity to
discuss concerns about medications and hear from respected
peers as to whether these concerns are valid. Generally,
clinicians also have the potential to modify or overcome
concerns in individual patients through open-ended and
collaborative communication.42, 43 Counseling strategies,
such as motivational interviewing in particular, have been
successful at increasing medication adherence in some
studies conducted in minority populations.44 However, in
order to be successful, clinicians are encouraged to assess
patients’ concerns about medications.
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